K
Kiora Pharmaceuticals D
D
KPRX
3.46000
USD
-0.03
(-0.86%)
مغلق
حجم التداول
306
الربح لكل سهم
-2
العائد الربحي
-
P/E
3
حجم السوق
10,382,726
المقالات
العنوان: Kiora Pharmaceuticals Inc.
القطاع: Healthcare
الصناعة: Biotechnology
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.